SCYX Stock Analysis: Buy, Sell, or Hold?
SCYX - SCYNEXIS, Inc.
$4.09
-0.14 (-3.31%)
▼
5d:
-8.09%
30d:
+430.62%
90d:
+354.95%
HOLD
LOW Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When SCYX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SCYX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SCYX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: SCYX is currently trading at $4.09, which is considered slightly high relative to its 30-day fair value range of $0.45 to $4.27. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.6) compared to its historical average (1.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCYX is in a uptrend. Immediate support is located at $0.68, while resistance sits at $5.62. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: SCYX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.55 (+720.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SCYX is in a uptrend. Immediate support is located at $0.68, while resistance sits at $5.62. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: SCYX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.55 (+720.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.45 -
$4.27
Company Quality Score
54/100
(HOLD)
Options IV Signal
33th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.0%
All Signals
- NEUTRAL: Options fairly priced (IV 33th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 720.2% below Wall St target ($33.55)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -8.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.45 -
$4.27
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.59
(14.4%)
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$5.62
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.62
Wall Street Target
$33.55
(+720.2%)
Revenue Growth (YoY)
1808.5%
Profit Margin
-120.5%
PE vs Historical
-1.6 vs 1.5
CHEAP
Share & Embed Analysis
Last updated: June 16, 2026 12:19 AM ET
Data refreshes hourly during market hours. Next update: 1:19 AM
Data refreshes hourly during market hours. Next update: 1:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCYX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 61 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 61 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 58 HOLD |
